Looking forward, Beta Bionics provided its first 2025 revenue guidance, which aligns with current consensus estimates. The company forecasts revenues to be between $80-85 million, which is consistent with Stifel's and the consensus estimate of $83 million. Additionally, the company anticipates gross margins to exceed 50% and expects the full-year pharmacy mix to be greater than 20%. This guidance surpasses Stifel's earlier estimate of a 13% pharmacy mix, indicating potential upside in the coming years. The analysts emphasized that an increase in pharmacy distribution over a four-year period would likely lead to higher per-patient revenue for Beta Bionics. With these considerations, Stifel maintains their Buy rating and a $25.00 price target on the stock, reflecting confidence in the company's future performance and market potential. Based on InvestingPro 's Fair Value analysis, the stock appears slightly overvalued at current levels.